Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study

被引：0
|
作者：
Zhao, Jinbo [1 ]
Yan, Xiaolong [1 ]
Bai, Yuquan [1 ]
Duan, Hongtao [1 ]
Jiang, Tao [1 ]
机构：
[1] Air Force Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14633
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
  • [2] Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
    Zhang, Zhi
    Ye, Jinjun
    Li, Hui
    Gu, Dayong
    Du, Mingyu
    Ai, Dashan
    Chen, Wei
    Fang, Ying
    Xu, Xinyu
    Bai, Chenguang
    Zhao, Kuaile
    Zhou, Guoren
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
    Park, Sehhoon
    Lee, Yurimi
    Lee, Jiyun
    Min, Yang Won
    Kim, Hong Kwan
    Choi, Joon Young
    Jung, Hyun Ae
    Choi, Yong Soo
    Choi, Yoon-La
    Shim, Young Mog
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 567 - 579
  • [4] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE)
    Chen, Yuzhen
    Ren, Meiyu
    Li, Bin
    Meng, Yuqi
    Wang, Cheng
    Jiang, Peng
    Song, Tieniu
    Yang, Jianbao
    Zhu, Duojie
    Yu, Qiyao
    JOURNAL OF THORACIC DISEASE, 2023, 15 (12) : 6761 - 6775
  • [6] Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
    Wang, Jianping
    Zhang, Jian
    Gao, Jie
    Zhao, Mengmeng
    Ma, Zhenkai
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 573 - 581
  • [7] Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study
    Jin, Peng
    Gao, Yong Sheng
    Fu, Zheng
    Yang, Wen Feng
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
    He, J.
    Zhao, L.
    Li, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1553 - S1553
  • [9] Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
    Li, Jingpei
    Liu, Jun
    Li, Zhuoyi
    Cui, Fei
    Zeng, Yuan
    Liang, Wenhua
    Liang, Hengrui
    Wang, Wei
    Xu, Ke
    Cai, Weipeng
    Fu, JunHui
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Ding, Chengzhi
    Guo, Yijun
    Zhou, Yaning
    He, Yi
    Chen, Chunji
    Zhang, Ming
    Guo, Xufeng
    BMC CANCER, 2023, 23 (01)
12345